项目编号 PRJCA016396
项目标题 RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumor immunity
涉及领域 Medical
数据类型 Transcriptome or Gene expression
Raw sequence reads
物种名称 Mus musculus
描述信息 RIG-I is a pattern recognition receptor involved in innate immunity, but its role in adaptive immunity remains unclear. Here, we demonstrate that RIG-I is upregulated in tumor infiltrating CD8+ T cells, where it functions as an intracellular checkpoint to negatively regulate CD8+ T cell function and limit antitumor immunity. Mechanically, up-regulation of RIG-I in CD8+ T cells is induced by retinoic acid (RA), a metabolite of vitamin A in TME, and direct inhibits the AKT/glycolysis signaling pathway. In addition, deletion of RIG-I enhances the efficacy of adoptively transferred T cells against solid tumors and inhibition of RIG-I enhances the response to PD-1 blockade. Our findings identify RIG-I as an intracellular checkpoint and a potential target for alleviating inhibitory constraints on T cells in cancer immunotherapy, either alone or in combination with immune checkpoint blockade.
样品范围 Multiisolate
发布日期 2023-04-25
出版信息
PubMed ID 文章标题 杂志名称 Doi 发表年份
39322862 RIG-I is an intracellular checkpoint that limits CD8 + T-cell antitumour immunity EMBO Molecular Medicine 10.1038/s44321-024-00136-9 2024
项目资金来源
机构 项目类型 授权项目ID 授权项目名称
National Natural Science Foundation of China (NSFC) 82103433
National Natural Science Foundation of China (NSFC) 82204415
National Natural Science Foundation of China (NSFC) 32200936
Guangdong Basic and Applied Basic Research Foundation 2020A1515110013
Guangdong Basic and Applied Basic Research Foundation 2021A1515220187
Guangdong Basic and Applied Basic Research Foundation 2021A1515110561
Shenzhen Science and Technology Innovation Commission projects JCYJ20220818101808018
提交者 ligong lu (luligong1969@jnu.edu.cn)
提交单位 Zhuhai People's Hospital Affiliated with Jinan University
提交日期 2023-04-19

项目包含数据信息

资源名称 描述
BioSample (9)  show -
GSA (1) -
CRA010683 RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumor immunity